Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells

Frontiers in Immunology

Volumn 7, Issue , 2016, Pages

  König, Martin ^a   Rharbaoui, Faiza ^a   Aigner, Silke ^a   Dälken, Benjamin ^a   Schüttrumpf, Jörg ^a  

^a BIOTEST AG   (Germany)

Author keywords

autoimmunity; CD4 T cells; monoclonal antibody; regulatory T cells; rheumatoid arthritis

Indexed keywords

EID: 84984812478     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00011     Document Type: Review

References (77)

1. Sakaguchi S Sakaguchi N Asano M Itoh M Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 155:1151–64.7636184
2. Jiang S. Regulatory T cells: from bench to bedside. Int Immunopharmacol (2009) 9(5):515–7.10.1016/j.intimp.2008.01.03819272465
3. Notley C Ehrenstein M. The yin and yang of regulatory T cells and inflammation in RA. Nat Rev Rheumatol (2010) 6(10):572–7.10.1038/nrrheum.2010.14320808295
4. Bluestone JA Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 3(3):253–7.10.1038/nri103212658273
5. Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol (2011) 707:3–17.10.1007/978-1-61737-979-6_121287325
6. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 6(4):345–52.10.1038/ni117815785760
7. + regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther (2004) 6(4):R335–46.10.1186/ar119215225369
8. Miyara M Gorochov G Ehrenstein M Musset L Sakaguchi S Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev (2011) 10(12):744–55.10.1016/j.autrev.2011.05.00421621000
9. + T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol (2005) 140(2):360–7.10.1111/j.1365-2249.2005.02754.x15807863
10. + regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype and function between peripheral blood and synovial fluid. Arthritis Rheum (2004) 50(9):2775–85.10.1002/art.20499
11. +CD25 high regulatory T cell population in peripheral blood. Rheumatology (2006) 45(10):1210–7.10.1093/rheumatology/kel08916571607
12. + regulatory T cells in inflamed synovia. J Exp Med (2005) 201(11):1793–803.10.1084/jem.2005008515939793
13. +CD25hi T-regulatory cells. Blood (2006) 108(1):253–61.10.1182/blood-2005-11-456716537805
14. + T cell-mediated suppression by dendritic cells. Science (2003) 299(5609):1033–6.10.1126/science.1078231
15. Nelson BH. IL-2, regulatory T cells and tolerance. J Immunol (2004) 172(7):3983–8.10.4049/jimmunol.172.7.398315034008
16. + regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today (2007) 12(13–14):548–52.10.1016/j.drudis.2007.05.00217631249
17. + regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum (2007) 56(3):732–42.10.1002/art.2241417328044
18. + T regulatory cells. J Immunol (2007) 179(1):154–61.10.4049/jimmunol.179.1.15417579033
19. Nagar M Jacob-Hirsch J Vernitsky H Berkun Y Ben-Horin S Amariglio N et al. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J Immunol (2010) 184(7):3570–81.10.4049/jimmunol.090207020181891
20. + cells. Semin Immunol (2006) 18(2):78–88.10.1016/j.smim.2006.01.00616458015
21. Brunstein CG Miller JS Cao Q McKenna DH Hippen KL Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2011) 117(3):1061–70.10.1182/blood-2010-07-29379520952687
22. Di Ianni M Falzetti F Carotti A Terenzi A Castellino F Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood (2011) 117(14):3921–8.10.1182/blood-2010-10-31189421292771
23. von Boehmer H Daniel C. Therapeutic opportunities for manipulating T(reg) cells in autoimmunity and cancer. Nat Rev Drug Discov (2013) 12(1):51–63.10.1038/nrd368323274471
24. Pere H Tanchot C Bayry J Terme M Taieb J Badoual C et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1(3):326–33.10.4161/onci.1885222737608
25. + regulatory T cells using a novel cell-based high throughput screening assay. Biochem Pharmacol (2013) 85(10):1513–24.10.1016/j.bcp.2013.03.01323537702
26. Byng-Maddick R Ehrenstein MR. The impact of biological therapy on regulatory T cells in rheumatoid arthritis. Rheumatology (Oxford) (2015) 54(5):768–75.10.1093/rheumatology/keu48725667434
27. Ehrenstein MR Evans JG Singh A Moore S Warnes G Isenberg DA et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. J Exp Med (2004) 200(3):277–85.10.1084/jem.20040165
28. McGovern JL Nguyen DX Notley CA Mauri C Isenberg DA Ehrenstein MR. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum (2012) 64(10):3129–38.10.1002/art.3456522674488
29. Housley WJ Adams CO Nichols FC Puddington L Lingenheld EG Zhu L et al. Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. J Immunol (2011) 186(12):6779–87.10.4049/jimmunol.100386821572024
30. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun (2010) 11:180–210.10.1159/00028920520173395
31. Takeuchi T Tanaka Y Amano K Hoshi D Nawata M Nagasawa H et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology (2011) 50(10):1908–15.10.1093/rheumatology/ker221
32. Taylor PC Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol (2009) 5(10):578–82.10.1038/nrrheum.2009.18119798034
33. Cohen S Hurd E Cush J Schiff M Weinblatt ME Moreland LW et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 46(3):614–24.10.1002/art.1014111920396
34. Fleishmann R. Anakinra in the treatment of rheumatic disease. Expert Rev Clin Immunol (2006) 2(3):331–40.10.1586/1744666X.2.3.33120476905
35. Assier E Boissier MC Dayer JM. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine (2010) 77(6):532–6.10.1016/j.jbspin.2010.07.00720869898
36. Boisser MC Assier E Falgarone G Bessis N. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine (2008) 75(4):373–5.10.1016/j.jbspin.2008.04.005
37. Heuber AJ Asquith DL Miller AM Reilly J Kerr S Leipe J et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol (2010) 184(7):3336–40.10.4049/jimmunol.090356620200272
38. Genovese M Van den Bosch F Roberson SA Bojin S Biagini IM Ryan P et al. LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase 1 randomized double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum (2010) 62(4):929–39.10.1002/art.27334
39. Kuhns MS Davis MM Garcia KC. Deconstructing the form and function of the TCR/CD3 complex. Immunity (2006) 24(2):133–9.10.1016/j.immuni.2006.01.00616473826
40. Genovese M Durez P Richards H Hugot S Thangavelu K Mpofu S. Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: results of a Phase IIb study. Arthritis Rheum (2011) 63(Suppl 10):401.
41. Genovese MC Becker JC Schiff M Luggen M Sherrer Y Kremer J et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 353(11):1114–23.10.1056/NEJMoa05052416162882
42. Genovese MC Covarrubias A Leon G Mysler E Keiserman M Valente R et al. Subcutaneous abatacept versus intravenous abatacept: a Phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum (2011) 63(10):2854–64.10.1002/art.3046321618201
43. Kremer JM Dougados M Emery P Durez P Sibilia J Shergy W et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatercept: twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 52(8):2263–71.10.1002/art.21201
44. Leffers HC Ostergaard M Glintborg B Krogh NS Foged H Tarp U et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis (2011) 70(7):1216–22.10.1136/ard.2010.14012921551512
45. + Treg cells and induces sustained amelioration of collagen-induced arthritis. Arthritis Rheum (2009) 62(1):171–8.10.1002/art.25058
46. Chatenoud L Baudrihaye MF Kreis H Goldstein G Schindler J Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol (1982) 12(11):979–82.10.1002/eji.18301211166759145
47. Chatenoud L Thervet E Primo J Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 91(1):123–7.10.1073/pnas.91.1.1238278351
48. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs (2011) 3(1):76–99.10.4161/mabs.3.1.1389521051951
49. Herold KC Hagopian W Auger JA Poumian-Ruiz E Taylor L Donaldson D et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 346(22):1692–8.10.1056/NEJMoa01286412037148
50. Sherry N Hagopian W Ludvigsson J Jain SM Wahlen J Ferry RJ Jr et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 378(9790):487–97.10.1016/S0140-6736(11)60931–821719095
51. Keymeulen B Walter M Mathieu C Kaufman L Gorus F Hilbrands R et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 53(4):614–23.10.1007/s00125-009-1644-920225393
52. ClinicalTrials.gov. Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis (2015). Available from: www.clinicaltrials.gov/show/nct01077531
53. ClinicalTrials.gov. Repeat Dose Subcutaneous Rheumatoid Arthritis Efficacy Study (2015). Available from: www.clinicaltrials.gov/show/nct01101555
54. Bresson D von Herrath M. Humanizing animal models: a key to autoimmune diabetes treatment. Sci Transl Med (2011) 3(68):68s4.10.1126/scitranslmed.300210221289271
55. + immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol (2004) 16(2):81–8.10.1016/j.smim.2003.12.003
56. Strand V Kimberly R Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov (2007) 6(1):75–92.10.1038/nrd219617195034
57. Duarte J Agua-Doce A Oliveira VG Fonseca JE Graca L. Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One (2010) 5(5):e10558.10.1371/journal.pone.001055820479941
58. Pascher A Proesch S Pratschke J Reutzel-Selke A Sawitzki B Lehmann M et al. Rat cytomegalovirus infection interferes with anti-CD4 mAb-(RIB 5/2) mediated tolerance and induces chronic allograft damage. Am J Transplant (2006) 6(9):2035–45.10.1111/j.1600-6143.2006.01453.x16869800
59. Moreland LW Pratt PW Mayes MD Postlethwaite A Weisman MH Schnitzer T et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum (1995) 38(11):1581–8.10.1002/art.17803811097488278
60. Schulze-Koops H Davis L Haverty P Wacholtz MC Lipsky PE. Reduction of Th1 cell activity in peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monocolonal antibody to CD4. J Rheumatol (1998) 25(11):2065–76.
61. Mason U Aldrich J Breedveld F Davis CB Elliott M Jackson M et al. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol (2002) 29(2):220–9.11838838
62. Reddy MP Kinney CAS Chaikin MA Payne A Fishman-Lobell J Tsui P et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol (2000) 164(4):1925–33.10.4049/jimmunol.164.4.192510657642
63. Hepburn TW Totoritis MC Davis CB. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis. Rheumatology (2003) 42(1):54–61.10.1093/rheumatology/keg03012509613
64. Luggen ME Schechtman J Kivitz A Greenwald M Forstot J Boling E et al. Results of a Phase II, double-blind, randomized study of a nondepleting anti-CD4 monoclonal antibody (clenoliximab) given in combination with methotrexate (mtx) in patients with moderate to severe rheumatoid arthritis (RA). Ann Rheum Dis (2003) 62(Suppl 2):O0004.
65. Choy EH Connolly DJ Rapson N Jeal S Brown JC Kingsley GH et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (2000) 39(10):1139–46.10.1093/rheumatology/39.10.113911035136
66. Choy E Panayi GS Emery P Madden S Breedveld FC Kraan MC et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (2002) 41(10):1142–8.10.1093/rheumatology/41.10.114212364634
67. Helling B König M Dälken B Engling A Krömer W Heim K et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol (2015) 93(4):396–405.10.1038/icb.2014.10225512343
68. Czeloth N Dälken B Engling A Osterroth F Aigner S Abufarag A et al. Selective activation of naturally occurring regulatory T cells (Tregs) by the monoclonal antibody BT-061 as a novel therapeutic opportunity: pre-clinical and early clinical results. Ann Rheum Dis (2010) 69(Suppl3):99.
69. Becker C Kubach J Wijdenes J Knop J Jonuleit H. CD4-mediated functional activation of human CD4+CD25+ regulatory T cells. Eur J Immunol (2007) 37(5):1217–23.10.1002/eji.20063648017407195
70. Mellor AL Munn DH. Physiologic control of the functional status of Foxp3+ regulatory T cells. J Immunol (2011) 186(8):4535–40.10.4049/jimmunol.100293721464094
71. Bopp T Becker C Klein M Klein-Hessling S Palmetshofer A Serfling E et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med (2007) 204(6):1303–10.10.1084/jem.2006212917502663
72. Ng CM Stefanich E Anand BS Fielder PJ Vaickus L. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res (2006) 23(1):95–103.10.1007/s11095-005-8814-316308668
73. Dokoupilova E Jeka S Vencovsky J Badurski J Prins K Strand V et al. Use of a biologic marker for an integrated pharmacodynamic and clinical analysis to inform further clinical development, including dose selection for the Phase 2b trial – Treat 2b – of tregalizumab in rheumatoid arthritis. Arthritis Rheum (2013) 65(Suppl 10):1412.
74. Abufarag A Aigner S Czeloth N Dälken B Koch H Niemann G et al. Selective activation of naturally occurring regulatory T cells (Tregs) by the monoclonal antibody BT-061 as a novel therapeutic opportunity in psoriasis: early clinical results after single doses. J Invest Dermatol (2010) 130(Issue 2):S64.
75. Rudnev A Ragavan S Trollmo C Malmstroem V Becker C Jonuleit H et al. Selective activation of naturally occurring regulatory T cells (Tregs) by the monoclonal antibody (mAb) BT-061. Markers of clinical activity and early Phase II results in patients with rheumatoid arthritis (RA). Arthritis Rheum (2010) 62(Suppl 10):1125.
76. ClinicalTrials.gov. Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) with Active Rheumatoid Arthritis (986) (2015). Available from: www.clinicaltrials.gov/show/nct01999192
77. van Vollenhoven RF Keystone EC Strand V Pacheco-Tena C Vencovsky J Behrens F et al. A Phase 2b study evaluating the efficacy and safety of subcutaneously administered tregalizumab in subjects with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX). Arthritis Rheumatol (2015) 67(Suppl 10). Available from: http://acrabstracts.org/abstract/a-phase-2b-study-evaluating-the-efficacy-and-safety-of-subcutaneously-administered-tregalizumab-in-subjects-with-active-rheumatoid-arthritis-ra-despite-treatment-with-methotrexate-mtx/